Bristol-Myers Squibb Co., of New York, said the FDA approved anti-PD-1 drug Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAFV600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma, under the agency's accelerated approval pathway based on progression-free survival data. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.